1. Molecular screening of interleukin-6 gene promoter and influence of −174G/C polymorphism on breast cancer
- Author
-
Chérel, Michel, Campion, Loïc, Bézieau, Stéphane, Campone, Mario, Charrier, Josiane, Gaschet, Joëlle, Ricolleau, Gabriel, Gouraud, Wilfried, Charbonnel, Catherine, and Jézéquel, Pascal
- Subjects
- *
INTERLEUKIN-6 , *PROMOTERS (Genetics) , *GENETIC polymorphisms , *BREAST cancer prognosis , *CYTOKINES , *CARCINOGENESIS , *GENETIC testing ,CANCER pathophysiology - Abstract
Abstract: Interleukin-6 (IL-6) is a cytokine involved in different physiologic and pathophysiologic processes including carcinogenesis. In 2003, a single nucleotide polymorphism (−174G/C) of the IL-6 gene promoter has been linked to breast cancer prognosis in node-positive (N+) breast cancer patients. Since, different studies have led to conflicting conclusions about its role as a prognostic and/or diagnostic marker. The primary aim of our study was to investigate the link between −174G/C polymorphism and breast cancer risk on the one hand, and −174G/C polymorphism and prognosis in different groups of patients: sporadic N+breast cancers (n =138), sporadic N− breast cancers (n =95) and familial breast cancer (n =60) on the other hand. The variables of interest were disease-free survival and overall survival. The secondary aim of the study was to screen IL-6 gene promoter using direct sequencing to identify new polymorphisms in our French Caucasian breast cancer population. No association or trend of association between −174G/C polymorphism of IL-6 gene promoter gene and breast cancer diagnosis or prognosis was shown, even in meta-analyses. Furthermore, we have identified four novel polymorphic sites in the IL-6 gene promoter region: −764G→A, −757C→T, −233T→A, 15C→A. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF